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Abstract
European guidelines recommend the routine offer of an HIV test in patients with a number
of AIDS-defining and non-AIDS conditions believed to share an association with HIV; so
called indicator conditions (IC). Adherence with this guidance across Europe is not known.
We audited HIV testing behaviour in patients accessing care for a number of ICs. Participat-
ing centres reviewed the case notes of either 100 patients or of all consecutive patients in
one year, presenting for each of the following ICs: tuberculosis, non-Hodgkins lymphoma,
anal and cervical cancer, hepatitis B and C and oesophageal candidiasis. Observed HIV-
positive rates were applied by region and IC to estimate the number of HIV diagnoses
potentially missed. Outcomes examined were: HIV test rate (% of total patients with IC), HIV
test accepted (% of tests performed/% of tests offered) and new HIV diagnosis rate (%).
There were 49 audits from 23 centres, representing 7037 patients. The median test rate
across audits was 72% (IQR 32–97), lowest in Northern Europe (median 44%, IQR 22–
68%) and highest in Eastern Europe (median 99%, IQR 86–100). Uptake of testing was
close to 100% in all regions. The median HIV+ rate was 0.9% (IQR 0.0–4.9), with 29 audits
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(60.4%) having an HIV+ rate >0.1%. After adjustment, there were no differences between
regions of Europe in the proportion with >0.1% testing positive (global p = 0.14). A total of
113 patients tested HIV+. Applying the observed rates of testing HIV+ within individual ICs
and regions to all persons presenting with an IC suggested that 105 diagnoses were poten-
tially missed. Testing rates in well-established HIV ICs remained low across Europe,
despite high prevalence rates, reflecting missed opportunities for earlier HIV diagnosis and
care. Significant numbers may have had an opportunity for HIV diagnosis if all persons
included in IC audits had been tested.
Introduction
Late-stage diagnosis of HIV and undiagnosed HIV continue to be features of many European
HIV epidemics [1]. Despite extensive work and the widespread use of a consensus definition of
late presentation, 50% of patients newly diagnosed with HIV have a CD4 count<350 cells/uL
at diagnosis, negatively impacting both individual and public health [1–4]. Innovative
approaches to better target testing for those most likely to be infected with HIV and who pres-
ent late for care need to be developed. Studies suggest HIV testing will be cost-effective if the
detected HIV prevalence in such testing programmes exceeds 0.1% [5–8].
As described elsewhere [9], the pilot phase of the HIDES Study (HIV Indicator Diseases
across Europe Study) surveyed eight indicator conditions (ICs)–with 3588 individuals present-
ing with either sexually transmitted infections, malignant lymphoma, anal or cervical cancer,
herpes zoster, hepatitis B and C, ongoing mononucleosis-like illness, unexplained leukocytope-
nia and thrombocytopenia and seborrheic dermatitis offered an HIV test. Out of the 3588 indi-
viduals, 66 were diagnosed with HIV. All eight ICs individually fulfilled the study’s criteria of
demonstrating an HIV prevalence of>0.1%, however, for malignant lymphoma and anal and
cervical cancer, 0.1 fell within the 95% confidence interval. [9]. In line with ECDC (European
Centre for Disease Prevention and Control) guidance, the study demonstrated that individuals
presenting to any healthcare setting with HIV indicator conditions (ICs) should be strongly
recommended to have an HIV test [9–11].
Guidance for implementing HIV testing in adults in healthcare settings has been developed
by HIV in Europe and widely disseminated. A number of countries have translated the docu-
ment or included the recommendations in national testing guidelines/ recommendations [11].
The guidance divides HIV indicator conditions into three categories: 1) conditions which are
AIDS defining among people living with HIV (PLHIV); 2) conditions associated with an undi-
agnosed HIV prevalence of>0.1% and 3) conditions where not identifying the presence of HIV
infection may have significant adverse implications for the individual’s clinical management.
The present follow-up study, HIDES II, is expanding this testing strategy by increasing the
number of indicator conditions and centres involved to identify those ICs with an HIV preva-
lence of>0.1%, [8, 9], and to ascertain whether there is variation in prevalence across Europe.
Adherence to testing guidelines across Europe in the context of IC-guided testing is cur-
rently unknown. Therefore, a second objective of HIDES II is to implement and evaluate an
audit system across Europe of HIV testing of persons presenting with ICs where an HIV test
should already be offered according to contemporary HIV testing guidelines [10,11]. As the
pilot phase of HIDES identified a number of barriers to introducing IC-guided testing in “new”
ICs, the audits aimed to investigate whether HIV testing is more routinely offered in already
established ICs, and if regional differences exist.
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Methods
Six HIV indicator conditions were selected for auditing of HIV testing: tuberculosis (TB), hepa-
titis B and C (HEP), non-Hodgkin lymphoma (NHL), anal and cervical cancer (ACCAN) and
oesophageal candidiasis (ECAN). These conditions fall into the category of AIDS defining con-
ditions and/or conditions where the need for an HIV test is already widely accepted and should
be part of clinical practice according to European and national HIV testing guidelines [10,11].
Each audit assessed the HIV test rate for one specific indicator condition for a specific seg-
ment of the population within a specific setting. It included all consecutive patients> 18 and
<65 years of age, not known to be HIV positive, who had presented at the centre within the
previous year or the last 100 consecutive patients or more seen at the centre. Participating cen-
tres reviewed retrospectively how many patients presenting with the IC were tested for HIV.
Where data was available, information on the number of HIV tests offered and accepted (offer
and uptake rates) was recorded. Each participating centre could complete one audit per IC.
A call for collaboration was sent to healthcare centres/hospitals across the four regions of
Europe: North, East, South and West [12]. Centres were eligible for participation if they rou-
tinely saw patients with one or more of the six ICs and were selected based on an aim of deliv-
ering a balanced number of audits per IC and regionally within the study.
Data was collected retrospectively fromMay 2013. Centers reviewed medical reports and
submitted data electronically to the coordinating centre via an online CRF system (REDCap)
[13]. The offer rate was defined as number offered an HIV test divided by the number of
patients seen with unknown HIV status. The uptake rate was defined as the number tested for
HIV divided by the number offered a test. The test rate was defined as the number tested
divided by the number of patients seen with unknown HIV status and the HIV+ rate was
defined as the number testing HIV+ divided by the number of patients seen with unknown
HIV status. A high test rate was defined as a test rate above the median of 72% and a high offer
rate as a offer rate above the median of 86%.
All rates were standardised for duration of the audit and number of patients seen within a
calendar year. Data are reported as medians and interquartile ranges (IQR) across rates, as
individual patient data was not available.
ICs were combined to non-malignant AIDS (TB and oesophageal candidiasis), malignant
(NHL, anal and cervical cancer) and hepatitis to allow comparison across ICs. Regions were
defined according to regions defined in EuroSIDA [12].
As centres were not independent (i.e. more than one audit originated from a number of cen-
tres), generalised estimating equations with a binomial distribution was used to determine
odds of outcomes, using robust standard errors to account for repeated audits within centres.
Two primary outcomes were investigated: the odds of having a high test rate, defined as greater
than the median test rate across all audits, and a high testing positive rate, defined as>0.1%
testing positive, the cut-off used to determine economic viability [7,8].
As an additional exercise, observed HIV positivity rates were applied for each region and IC to
estimate the number of HIV diagnoses potentially missed. The HIV+ rate and 95% confidence
interval was applied within each region and IC to all patients seen over the relevant time period
to estimate the number of HIV positive diagnoses potentially missed, using the point estimate
and the lower and upper limit of the confidence limit of the HIV rate among those actually tested.
Results
Audit characteristics
There were 49 audits from 23 centres representing 7037 persons and the median period of time
for retrospective data collection was 1.5 years. Of the audits conducted, 11 (22.4%) were from
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each of Southern and Central Europe, 13 (26.5%) from Eastern, and 14 (28.6%) from Northern
Europe. There were 16 audits (32.7%) for TB (representing 1401 persons), 9 (18.4%, 1274 per-
sons) for NHL, 5 for anal cancer (10.2%, 531 persons), 6 for cervical cancer (12.2%, 583 per-
sons), 10 for hepatitis (20.4%, 2681 persons) and 3 (6.1%, 567 persons) for oesophageal
candidiasis. All regions performed audits on all ICs, with the exception of oesophageal candidi-
asis, with neither Southern nor Central Europe being represented. A summary of the audits is
shown in Table 1. The median number of audits per site was 3 (IQR 2–4), with a median num-
ber of 57 patients/year seen with a specific IC and not known to be HIV+ (IQR 20–140).
Testing rates per audit per region and per IC
The test rate was 72% overall (IQR 32–97), with the lowest rate in Northern Europe (median
44%, IQR 22–68%) and the highest in Eastern Europe (median 99%, IQR 86–100%). A high
test rate was defined as>72% of those seen with unknown HIV status being tested for HIV.
After adjustment for region, IC and the number of persons per audit, those from Northern
Europe were less likely to have a test rate>72% compared to those from Southern Europe
(adjusted odds ratio [aOR] 0.12; 95% CI 0.011–1.31, p = 0.082), and there was a weak, non-sig-
nificant association with number of patients seen per year. Compared to TB and oesophageal
candidiasis, those testing for NHL, anal and cervical cancer were less likely to have a high test
rate (aOR 0.078; 95% CI 0.0079–0.68, p = 0.021).
Test offer and uptake rates
Offer rates (number of patients with IC offered an HIV test) were available for 41/49 audits.
The offer rate for HIV testing was 86% overall (IQR 60–100%), with the lowest offer rate in
Northern Europe (median 69%, IQR 33–70) and the highest in Eastern Europe (median 100%,
IQR 97–100%). A high offer rate was defined as a rate of>86%. After adjustment, those from
northern Europe were less likely to have a high offer rate than those in Southern Europe (aOR
0.19; 95% CI 0.032–1.09, p = 0.062), although this was marginally statistically significant, possi-
bly due to the small sample size. There were no other regional differences and no association
with number of HIV- persons seen per year (p-value 0.80). Those presenting with cancer
Table 1. Summary of Audit Results.
Region All South Central North East
Audits (number, %) 49 100 11 22.4 11 22.4 14 28.6 13 26.5
Median IQR Median IQR Median IQR Median IQR Median IQR
Audit period (yr) 1.5 1.0–2.3 1.5 1.0–2.5 1.0 1.0–2.0 2.1 1.0–4.6 1.0 1.0–1.7
N Audits 3 2–4 3 2–4 3 2–3 2 1–5 3 3–4
N HIV-/yr 57 20–140 33 20–78 17 11–58 45 12–155 128 62–344
Offer rate1 86 60–100 77 26–98 86 72–91 69 33–70 100 97–100
Uptake rate2 100 100–100 100 99–100 100 100–100 100 98–100 100 100–100
Test rate 72 32–97 68 21–98 78 30–91 44 22–68 99 86–100
HIV+ rate per1000? 0.9 0.0–4.9 2.9 0.9–6.5 0.0 0.0–4.8 0.4 0.0–5.0 1.2 0.3–2.0
>0.1% HIV+*3 29 60.4 8 80.0 4 36.4 7 50.0 10 76.9
1calculated for 41 audits.
2calculated for 40 audits.
3calculated for 48 audits; one centre reported doing no tests and therefore no valid denominator
doi:10.1371/journal.pone.0140845.t001
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(NHL, anal or cervical) were less likely to have a high offer of testing compared to those pre-
senting with TB or oesophageal candidiasis (aOR 0.25; 95% CI 0.030–0.77, p = 0.016); no dif-
ferences were seen comparing TB/oesophageal candidiasis and hepatitis (p = 0.55).
The uptake of an offer of an HIV test was close to complete in all audits (95–100%) across
all regions and all IC audits, meaning that nearly all of those who were offered an HIV test
accepted to be tested.
HIV positivity rate per audit per region and per IC
The median HIV+ rate was 0.9% (IQR 0.0–4.9) (Fig 1) and was highest in Southern Europe
(2.9%) and Eastern Europe (1.2%). There was some variation in the proportions with a high
positive test rate (defined as>0.1%) across regions and across ICs, shown in Fig 1. Overall,
60.4% (29/48) audits had a positive rate>0.1%, ranging from 80.0% (8/10 audits) in Southern
Europe to 4/11 (36.4%) in Central Europe. All (3/3,100%) audits for oesophageal candidiasis
had a positive rate>0.1%.
After adjustment for number of patients, region and IC, compared to Southern Europe,
those from Central and North were less likely to have a high positive rate of>0.1% (aOR 0.30;
95% CI 0.078–1.14, p = 0.077 and 0.26; 95% CI 0.080–0.85, p = 0.026)), while those clinics test-
ing more patients were more likely to have a high positive rate (aOR 1.57/100 extra patients
seen; 95% CI 1.08–2.29, p = 0.019). Compared to TB and oesophageal candidiasis, those testing
for NHL, anal or cervical cancer were significantly less likely to have a high positive rate (aOR
Fig 1. Proportion with high HIV+ rate (>0.1%) across regions and ICs. The figure shows the audits with HIV positive rate < and >0.1% by region and by
Indicator Condition (IC).
doi:10.1371/journal.pone.0140845.g001
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0.21; 95% CI 0.48–0.89, p = 0.034), with no differences between TB/oesophageal candidiasis
and hepatitis (p = 0.39).
Potential missed HIV diagnoses
The number testing HIV+ was 113, and we estimate that 105 additional persons would have
tested HIV+ if the HIV+ rate within each IC and region was applied to all the persons repre-
sented by the audit. The HIV + rate within each IC and region was applied to all the persons
represented by the audit, not just those tested, to estimate the number of HIV+ diagnoses
potentially missed, together with how many would be missed if the HIV+ rate for each IC/
region was as low as the lower 95% CL or as high as the 95% CL, as shown in Table 2.
The HIV positivity rate within each IC and region was applied to all the persons represented
by the audits, not just those tested, to estimate the number of HIV positive diagnoses poten-
tially missed. The range of the total number missed is shown in parentheses.
Overall, if the rates of HIV+ were the same as those reported from the tested patients and
applied to all persons covered by the audit, we have potentially missed>100 diagnoses, includ-
ing 52 for NHL and 41 for OC. The number potentially missed from Southern Europe was 43
and 56 from Northern Europe. The total number of potentially missed HIV diagnoses was
either as low as 57 or as many as 226.
Discussion
The HIDES study group has successfully launched and implemented an audit system of HIV
indicator condition guided HIV testing in healthcare settings. The results show that persons
presenting to healthcare settings with conditions widely accepted as IC are not routinely HIV
tested. This is particularly true in Northern Europe, with potentially serious consequences for
some ICs, especially malignancies, where a high number of potential HIV diagnoses may have
been missed if the same rates applied in those not tested as those tested. This confirms previous
results showing how persons diagnosed late with HIV have in many cases been in contact with
the healthcare system prior to their HIV diagnosis [9,14–16].
The consequences of missing HIV diagnoses are many: for the individual health of the
patient, the public health by onward transmission risk and the increased costs to the health-
care system. HIV testing therefore needs to be integrated into the routine healthcare for ICs in
healthcare settings across Europe.
That the uptake of testing is close to complete across regions and across ICs may indicate
that the acceptance of HIV testing is high among persons attending healthcare facilities for
other reasons. As patient data is not available from these audits, we cannot rule out that some
tests were performed without informed consent, increasing the reported test rates. However, in
Table 2. Potential Missed HIV Diagnoses, Including Upper and Lower Range.
Total South Central North East
Tuberculosis 8 (0, 50) 1 (0, 15) 1 (0, 8) 0 (0, 7) 5 (0, 20)
Non-Hodgkin lymphoma 52 (29, 84) 41 (29, 53) 0 (0, 4) 11 (0, 24) 0 (0, 3)
Anal cancer 0 0 0 0 0
Cervical cancer 0 (0, 2) 0 0 0 0 (0, 2)
Hepatitis B or C 4 (0, 31) 1 (0, 5) 0 3 (0, 10) 0 (0, 16)
Oesophageal candidiasis 41 (28, 59) 0 0 41 (28, 53) 0 (0, 6)
Total 105 (57, 226) 43 (29, 73) 1 (0, 12) 56 (28, 94) 5 (0, 47)
doi:10.1371/journal.pone.0140845.t002
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most clinical settings patients do not object to HIV testing, and high rates of acceptance of test-
ing in patients presenting with ICs are plausible [17].
Comparing the test rates and positivity rates shown in this study to the HIV screening of
pregnant women [18–27], it is noticeable how easily routine testing has been introduced in
this population group. This is perhaps because the test is not only for the health of the
mother, but potentially protecting the unborn child from a serious illness. Although infor-
mation on HIV test rates and positivity rates are scarce in the literature on HIV screening of
pregnant women, country prevalence data collected through official national statistics shows
that coverage of screening is very high. In many countries screening coverage is >90%, UK,
Ireland, Finland, Denmark and Estonia having nearly complete screening coverage [21–25].
There is evidence that coverage in Eastern Europe varies with rates ranging from 2% in Mac-
edonia to 99% in Estonia. Countries like Denmark and the UK reached their high screening
coverage in recent years following the introduction of policies recommending routine
screening of all pregnant women, showing the effectiveness of good policy and effective
implementation [26,27].
Overall, we found 29/49 audits had a positive rate>0.1%, compared to an undiagnosed
HIV positivity rate in pregnant women which is often<0.1%, meaning that the strategy of
screening in pregnancy is not a cost-effective intervention, although recommended as essential
pre-natal care. The positivity rate in several AIDS defining as well as non-AIDS defining condi-
tions in these audits exceeds the cost-effectiveness threshold of 0.1%. We recommend therefore
that the observed barriers to introduce routine HIV testing/screening for persons presenting
with defined HIV ICs should be addressed and lessons learned from the introduction of routine
screening of pregnant women in many countries.
Limitations
The data presented are the summary aggregate data from the audits. As individual patient-level
data were not available, it has not been possible to take patient variation and medical history
into account in the analysis. It is possible that clinics have over-reported HIV testing or that
significant changes have occurred in the short time since this audit was performed. The com-
paratively small number of audits performed has resulted in some uncertainty about the num-
ber of potentially missed diagnoses. It is also possible that clinicians have targeted the HIV
testing offered to those at perceived greatest risk of testing positive, which may mean that our
rate of testing positive is overestimated and that the number of missed diagnoses would be
smaller than estimated.
Conclusions
Testing rates in well-established HIV ICs remain surprisingly low in some regions of Europe
despite high prevalence rates, reflecting missed opportunities for earlier HIV diagnosis, treat-
ment and care. Offer rates were higher in Southern than in Northern Europe and in TB and
oesophageal candidiasis than in those presenting with NHL, anal or cervical cancer. A signifi-
cant number (>100) of individuals may have had an earlier opportunity for HIV diagnosis.
This also assumes that the same number of people had tested positive among those not offered
an HIV test.
The high positivity rate observed through the HIDES study in both AIDS defining and non
AIDS defining ICs strongly reinforces the strategy of IC-guided HIV testing, both from the
individual and public health perspective. It is recommended that regular auditing of HIV test-
ing in ICs is introduced across Europe. The system developed by HIV in Europe can be easily
applied in national and European contexts (www.hiveurope.eu).
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